CD8A and neoplasm: With the modulation of immunosuppressive MDSCs and TAMs in the TME, the increased levels of CD8+ T cells and IFN-γ secretion in the tumor and spleen mediated by iGel could also change checkpoint therapy non-responding tumors into checkpoint therapy-responding tumors.